{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:34:10Z","timestamp":1790138050856,"version":"4.0.1"},"reference-count":74,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aggressive non-Hodgkin\u2019s lymphomas can be cured in more than half of the cases. However, there has been great variation in the results reported from individual clinical Phase II trials. This variation in result can be attributed to unrecognized heterogeneity in this group of diseases. Recent clinical and molecular studies have enabled us to define more homogenous population in which new therapies can be studied. For patients with advanced stages of diffuse large B cell lymphoma, a new standard of therapy exists. For patients with localized aggressive non-Hodgkin\u2019s lymphomas, heterogeneity in patient selection prevents us from defining a new standard of care. Finally, in mantle cell lymphoma, new opportunities in drug discovery may permit advances in the treatment of this uniformly fatal malignancy.<\/jats:p>\n               <jats:p>In Section I, Dr. Richard Fisher reviews the development of combination chemotherapy for patients with advanced stage diffuse large B cell lymphoma. Because of great heterogeneity in patients enrolled in Phase II studies, large randomized Phase III studies were required in the 1980s to define CHOP has the standard of care. This heterogeneity has now been defined carefully in the international prognostic factor index and more recently by gene array studies. It will now need to be incorporated prospectively into studies or retrospectively analyzed to understand clinical trial results. The addition of rituximab to CHOP has now been demonstrated to improve survival in two large Phase III studies in elderly patients. A recently presented study in younger patients suggests a similar benefit. Thus CHOP\/rituximab has become the established standard of care for all patients with advanced stage diffuse large B cell lymphoma. Other concepts being evaluated to further improve on these results include: dose intensification; initial treatment with chemotherapy plus allogeneic stem cell transplantation; and infusional chemotherapy. Finally, the status of the treatment for relapsed patients will be defined.<\/jats:p>\n               <jats:p>In Section II, Dr. Thomas Miller defines the treatment for limited stage aggressive non-Hodgkin\u2019s lymphoma. Randomized trials have demonstrated the critical importance of initial chemotherapy for treatment of these patients. The amount of chemotherapy given needs to be increased for patients with bulky tumors. In most circumstances radiotherapy after the completion of chemotherapy has been shown to be advantageous. A modification of the international prognostic factor index for patients with early stage disease is presented to permit comparisons among different populations. Recently reported early-stage studies need to be analyzed in terms of the heterogeneity of the patients involved to understand the reported results. The addition of monoclonal antibodies, as well as radioimmunotherapy, are being tested in an effort to improve on the results for the poor prognosis patients.<\/jats:p>\n               <jats:p>In Section III, Dr. Owen O\u2019Connor describes the pathology immunophenotype and natural history of mantle cell lymphoma. Conventional treatment strategies with combination chemotherapy achieved objective responses in approximately half of the patients but no significant impact on survival. The addition to rituximab to CHOP chemotherapy or other treatment strategies appears to improve the remission rate; however, no major changes in survival have also been reported. Excellent single institution results have been reported with HyperCVAD plus rituximab regimen, which is currently being tested in a national cooperative group trial. The most excitement in this field currently relates to the variety of new agents which appear to have significant activity in relapsed patients with mantle cell lymphoma. This includes the proteosome inhibitor, bortezomib, which is shown to have approximately a 50% response rate with some CRs and reasonable durability in early single institution Phase II studies. Larger national multi-center trials are ongoing. In addition, agents such as thalidomide, flavopiridol, and piroxantrone will be reviewed.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.221","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"221-236","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Diffuse Aggressive Lymphoma"],"prefix":"10.1182","volume":"2004","author":[{"given":"Richard I.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215272709100_R1","doi-asserted-by":"crossref","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328:1002\u20131006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"2020021215272709100_R2","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2020021215272709100_R3","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937\u20131947.","DOI":"10.1056\/NEJMoa012914"},{"key":"2020021215272709100_R4","doi-asserted-by":"crossref","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828\u20131837.","DOI":"10.1056\/NEJMoa032520"},{"key":"2020021215272709100_R5","doi-asserted-by":"crossref","unstructured":"Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68\u201374.","DOI":"10.1038\/nm0102-68"},{"key":"2020021215272709100_R6","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u2013242.","DOI":"10.1056\/NEJMoa011795"},{"key":"2020021215272709100_R7","unstructured":"Haberman TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood. 2003;102:6a."},{"key":"2020021215272709100_R8","doi-asserted-by":"crossref","unstructured":"Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients &lt; = 60 years with diffuse large B-cell non-Hodgkin\u2019s lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc ASCO; 2004:556a.","DOI":"10.1200\/jco.2004.22.90140.6500"},{"key":"2020021215272709100_R9","doi-asserted-by":"crossref","unstructured":"Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003;21:2466\u20132473.","DOI":"10.1200\/JCO.2003.06.137"},{"key":"2020021215272709100_R10","unstructured":"Pfreundschuh M, Truemper L, Kloess M, et al. 2-weekly vx. 3-weekly CHOP with and without etoposide for patients &gt; 60 years of age with aggressive non-Hodgkin\u2019s lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL. Ann Oncol. 2002;13 (supp 2)."},{"key":"2020021215272709100_R11","doi-asserted-by":"crossref","unstructured":"Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685\u20132693.","DOI":"10.1182\/blood.V99.8.2685"},{"key":"2020021215272709100_R12","doi-asserted-by":"crossref","unstructured":"Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin\u2019s lymphomas: Report of the jury. J Clin Oncol. 1999;17:423\u2013429.","DOI":"10.1200\/JCO.1999.17.1.423"},{"key":"2020021215272709100_R13","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u20131932."},{"key":"2020021215272709100_R14","doi-asserted-by":"crossref","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20131545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"2020021215272709100_R15","unstructured":"Miller TP, Jones SE. Chemotherapy of localized histiocytic lymphoma. Lancet. 1979;1:358\u2013360."},{"key":"2020021215272709100_R16","doi-asserted-by":"crossref","unstructured":"Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer. 1980;46:2356\u20132359.","DOI":"10.1002\/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X"},{"key":"2020021215272709100_R17","doi-asserted-by":"crossref","unstructured":"Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 1987;107:25\u201330.","DOI":"10.7326\/0003-4819-107-1-25"},{"key":"2020021215272709100_R18","doi-asserted-by":"crossref","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared to chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u201326.","DOI":"10.1056\/NEJM199807023390104"},{"key":"2020021215272709100_R19","doi-asserted-by":"crossref","unstructured":"Fisher RI, DeVita VT, Johnson BL, et al. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med1997;63:177\u2013182.","DOI":"10.1016\/0002-9343(77)90230-3"},{"key":"2020021215272709100_R20","unstructured":"Reyes F, Lepage E, Munck JN, et al. Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: the LNH93-1 GELA study [abstract]. Blood. 2002;100:93a."},{"key":"2020021215272709100_R21","unstructured":"Miller TP, LeBlanc M, Spier C, et al. CHOP alone compare to CHOP plus radiotherapy for early state aggressive non-Hodgkin\u2019s lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial [abstract]. Blood. 2001;98:724a."},{"key":"2020021215272709100_R22","doi-asserted-by":"crossref","unstructured":"Shipp M for The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2020021215272709100_R23","doi-asserted-by":"crossref","unstructured":"Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2001;20:197\u2013204.","DOI":"10.1200\/JCO.20.1.197"},{"key":"2020021215272709100_R24","unstructured":"Fillet G, Bonnet C, Mounier N, et al. Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin\u2019s lymphoma. Results of the GELA LNH 93-4 study. Blood. 2003;100:92a."},{"key":"2020021215272709100_R25","doi-asserted-by":"crossref","unstructured":"Horning SJ, Weller E, Kyung Mann K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032\u20133038.","DOI":"10.1200\/JCO.2004.06.088"},{"key":"2020021215272709100_R26","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med2002;346:235\u2013242.","DOI":"10.1056\/NEJMoa011795"},{"key":"2020021215272709100_R27","unstructured":"Sehn LH, Donaldson J, Chanabhal M, et al. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC) [abstract]. Blood. 2003;102:29a."},{"key":"2020021215272709100_R28","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982;49:1429\u20131438.","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5"},{"key":"2020021215272709100_R29","doi-asserted-by":"crossref","unstructured":"Palutke M, Eisenberg L, Mirchandani I, et al. Malignant lymphoma of small cleaved lymphocytes of the follicular mantle zone. Blood. 1982;59:317\u2013312.","DOI":"10.1182\/blood.V59.2.317.317"},{"key":"2020021215272709100_R30","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Armitage JO. Mantle cell lymphoma\u2014an entity comes of age. Blood. 1996;87:4483\u20134494.","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"2020021215272709100_R31","doi-asserted-by":"crossref","unstructured":"Raffeld M, Jaffe ES: bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259\u2013263.","DOI":"10.1182\/blood.V78.2.259.259"},{"key":"2020021215272709100_R32","doi-asserted-by":"crossref","unstructured":"Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16:637\u2013640.","DOI":"10.1097\/00000478-199207000-00001"},{"key":"2020021215272709100_R33","doi-asserted-by":"crossref","unstructured":"Barista I, Romaguera JE, Cabanillas F: Mantle-cell lymphoma. Lancet Oncol. 2001;2:141\u2013148.","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"2020021215272709100_R34","doi-asserted-by":"crossref","unstructured":"Duggan MJ, Weisenburger DD, Ye YL, et al. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer. 1990;66:522\u2013529.","DOI":"10.1002\/1097-0142(19900801)66:3<522::AID-CNCR2820660320>3.0.CO;2-4"},{"key":"2020021215272709100_R35","doi-asserted-by":"crossref","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075\u20131082.","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"2020021215272709100_R36","doi-asserted-by":"crossref","unstructured":"Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619\u2013626.","DOI":"10.1182\/blood.V95.2.619"},{"key":"2020021215272709100_R37","doi-asserted-by":"crossref","unstructured":"Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 1995;86:2892\u20132899.","DOI":"10.1182\/blood.V86.8.2892.2892"},{"key":"2020021215272709100_R38","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u2013197.","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"2020021215272709100_R39","doi-asserted-by":"crossref","unstructured":"Bertoni F, Zucca E, Cotter FE: Molecular basis of mantle cell lymphoma. Br J Haematol. 2004;124:130\u2013140.","DOI":"10.1046\/j.1365-2141.2003.04761.x"},{"key":"2020021215272709100_R40","doi-asserted-by":"crossref","unstructured":"Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. 1989;7:365\u2013380.","DOI":"10.1002\/hon.2900070505"},{"key":"2020021215272709100_R41","doi-asserted-by":"crossref","unstructured":"Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1995;13:2819\u20132826.","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"2020021215272709100_R42","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922\u20131930.","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"2020021215272709100_R43","doi-asserted-by":"crossref","unstructured":"Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995;6:257\u2013262.","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"2020021215272709100_R44","doi-asserted-by":"crossref","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567\u2013575.","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"2020021215272709100_R45","doi-asserted-by":"crossref","unstructured":"Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas\u2014results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood. 2004 Jul 29. [Epub ahead of print]","DOI":"10.1182\/blood-2004-04-1323"},{"key":"2020021215272709100_R46","doi-asserted-by":"crossref","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288\u20131294.","DOI":"10.1200\/JCO.20.5.1288"},{"key":"2020021215272709100_R47","doi-asserted-by":"crossref","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803\u20133809.","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"2020021215272709100_R48","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplanation in first remission in patients with diffuse mantle cell lymphoma. Cancer. 2003;98:2630\u20132635.","DOI":"10.1002\/cncr.11838"},{"key":"2020021215272709100_R49","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000;39:77\u201385.","DOI":"10.3109\/10428190009053541"},{"key":"2020021215272709100_R50","unstructured":"Romaguera J, Cabanillas F, Dang NH, Goy A, Hagemeister FB, Fayad L. Mantle cell lymphoma (MCL)\u2014high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT) [abstract]. Blood. 2001;98:726a."},{"key":"2020021215272709100_R51","doi-asserted-by":"crossref","unstructured":"Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682\u2013685.","DOI":"10.1126\/science.7624798"},{"key":"2020021215272709100_R52","doi-asserted-by":"crossref","unstructured":"Marshansky V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol. 2001;166:3130\u20133142.","DOI":"10.4049\/jimmunol.166.5.3130"},{"key":"2020021215272709100_R53","unstructured":"Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1:841\u2013849."},{"key":"2020021215272709100_R54","doi-asserted-by":"crossref","unstructured":"Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A. 1998;95:15671\u201315676.","DOI":"10.1073\/pnas.95.26.15671"},{"key":"2020021215272709100_R55","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420\u20134427.","DOI":"10.1200\/JCO.2002.01.133"},{"key":"2020021215272709100_R56","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. In press."},{"key":"2020021215272709100_R57","doi-asserted-by":"crossref","unstructured":"Goy A, Younes A, McLaughlin P, et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin\u2019s lymphomas (NHL) [abstract]. Proc ASCO.2004;23:#6581.","DOI":"10.1200\/jco.2004.22.14_suppl.6581"},{"key":"2020021215272709100_R58","unstructured":"Assouline S, Belch, A., Sehn, L., et al. A phase II study of bortezomib in patients with mantle cell lymphoma [abstract]. Blood. 2003;102:#3358."},{"key":"2020021215272709100_R59","doi-asserted-by":"crossref","unstructured":"Coleman M, Leonard J, Lyons L, et al. Treatment of Waldenstrom\u2019s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol. 2003;30:270\u2013274.","DOI":"10.1053\/sonc.2003.50044"},{"key":"2020021215272709100_R60","doi-asserted-by":"crossref","unstructured":"Damaj G, Lefrere F, Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17:1914\u20131915.","DOI":"10.1038\/sj.leu.2403058"},{"key":"2020021215272709100_R61","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Raderer M, Woehrer S, et al. Anti-tumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2004.","DOI":"10.1182\/blood-2004-03-1091"},{"key":"2020021215272709100_R62","doi-asserted-by":"crossref","unstructured":"Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992;84:1736\u20131740.","DOI":"10.1093\/jnci\/84.22.1736"},{"key":"2020021215272709100_R63","unstructured":"Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001;7:4209\u20134219."},{"key":"2020021215272709100_R64","unstructured":"Motwani M, Rizzo C, Sirotnak F, et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther. 2003;2:549\u2013555."},{"key":"2020021215272709100_R65","doi-asserted-by":"crossref","unstructured":"Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:1740\u20131745.","DOI":"10.1200\/JCO.2003.09.057"},{"key":"2020021215272709100_R66","doi-asserted-by":"crossref","unstructured":"Beggiolin G, Crippa L, Menta E, et al. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori. 2001;87:407\u2013416.","DOI":"10.1177\/030089160108700611"},{"key":"2020021215272709100_R67","unstructured":"Bertazzoli C, Bellini O, Magrini U, et al. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 1979;63:1877\u20131883."},{"key":"2020021215272709100_R68","unstructured":"Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin\u2019s lymphomas. Haematologica. 2003;88:888\u2013894."},{"key":"2020021215272709100_R69","doi-asserted-by":"crossref","unstructured":"Schrader C, Meusers P, Brittinger G, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18:1200\u20131206.","DOI":"10.1038\/sj.leu.2403387"},{"key":"2020021215272709100_R70","doi-asserted-by":"crossref","unstructured":"Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res. 2004;10:3029\u20133034.","DOI":"10.1158\/1078-0432.CCR-03-0554"},{"key":"2020021215272709100_R71","doi-asserted-by":"crossref","unstructured":"Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc Natl Acad Sci U S A. 2001;98:10320\u201310325.","DOI":"10.1073\/pnas.171060098"},{"key":"2020021215272709100_R72","doi-asserted-by":"crossref","unstructured":"Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002;296:1655\u20131657.","DOI":"10.1126\/science.296.5573.1655"},{"key":"2020021215272709100_R73","unstructured":"Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504\u20133513."},{"key":"2020021215272709100_R74","unstructured":"Witzig T, Geyer S, Salim M, et al. A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell Non-hodgkin\u2019s lymphoma: interim analysis of 18 patients [abstract]. Blood. 2003;102:#2374."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/221\/1634415\/221_236ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/221\/1634415\/221_236ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:27:52Z","timestamp":1581539272000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/221\/18673\/Diffuse-Aggressive-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.221","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}